Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical United States Regulation

Keeping Track: Two Melanoma Approvals; Pfizer Discloses Retacrit Complete Response

  • Analysis

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

You may also be interested in...



Bristol Offers Yervoy For Free In New Early Melanoma Indication

New program gives free treatment with the checkpoint inhibitor for up to three years to patients taking 10 mg/kg dose as adjuvant therapy after surgery.

Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines

Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical United States Regulation
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS057236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By